You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Infectious Diseases
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Login
Username:

Password:


Related Headlines

INOVIO announces inducement grant to new employee

Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays

Appili Therapeutics and Vitalex Biosciences secure NIAID contract for fungal vaccine development for up to USD40m

LakeShore Biopharma receives Nasdaq delisting determination letter

CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio

INOVIO to release Q2 2025 financial results on 12 August

Bavarian Nordic chikungunya vaccine enters Health Canada review process

Ondine Biomedical completes world-first ICU study with Steriwave nasal therapy

Senhwa Biosciences reports first patient dosed in Pidnarulex (CX-5461) study in patients with advanced solid tumours

Centivax raises USD45m to commercialise universal flu vaccine

SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval 

INOVIO prices USD25m public offering

Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC

Seegene launches STAgora infectious disease analytics platform

hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2025